{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:32:15Z","timestamp":1790721135340,"version":"4.1.0"},"reference-count":29,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Teclistamab is a bispecific antibody targeting BCMA and CD3, approved for relapsed\/refractory multiple myeloma. It is administered continuously until progression or intolerance; however, prolonged use may increase infections and treatment burden. This study compares continuous versus fixed-duration teclistamab to determine whether treatment discontinuation after response is feasible without compromising outcomes. Methods: A multicenter retrospective study was conducted on adults with relapsed\/refractory multiple myeloma treated with teclistamab between August 2022 and May 2024. Patients received step-up dosing followed by weekly administration. Those who achieved \u2265VGPR and discontinued therapy due to deep response, toxicity, or preference were assigned to the fixed-duration group. Outcomes included response rates, progression-free survival (PFS), overall survival (OS), and adverse events. Results: Eighty-eight patients were included (continuous: n = 72; fixed: n = 16). The fixed group had higher complete response rates (69% vs. 44%) and shorter median time to best response (1 vs. 2 months). Median PFS was 16 months for continuous dosing versus 13 months for fixed-duration. Twelve-month PFS was similar (65% vs. 66%). Twelve-month OS was 83% vs. 81% in the continuous and fixed groups, respectively. Cytokine release syndrome and neurotoxicity rates were similar. Infections were more frequent and severe in the fixed cohort (75% any grade; 69% grade \u2265 3). Conclusions: Fixed-duration teclistamab after deep response appears feasible in appropriately selected patients, with comparable early survival outcomes to continuous treatment. Prospective studies are needed to define selection criteria, immune recovery markers, and optimal discontinuation timing.<\/jats:p>","DOI":"10.3390\/cancers17213569","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T07:58:05Z","timestamp":1762329485000},"page":"3569","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Teclistamab Dosing Strategies in Relapsed\/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals"],"prefix":"10.3390","volume":"17","author":[{"given":"Jordan","family":"Snyder","sequence":"first","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-7534","authenticated-orcid":false,"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[{"name":"Levine Cancer Center, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC 27103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Paul","sequence":"additional","affiliation":[{"name":"Levine Cancer Center, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC 27103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2166-2583","authenticated-orcid":false,"given":"Abdullah Mohammad","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Habib","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA"},{"name":"Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Shaikh","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Strouse","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5299-4233","authenticated-orcid":false,"given":"Omar","family":"Alkharabsheh","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7899-7078","authenticated-orcid":false,"given":"Anita","family":"Mazloom","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3168-2521","authenticated-orcid":false,"given":"Zahra","family":"Mahmoudjafari","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Umair","family":"Mushtaq","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7537-0112","authenticated-orcid":false,"given":"Anas","family":"Zayad","sequence":"additional","affiliation":[{"name":"Department of Internal of Medicine, Hamad Medical Corporation, Doha P.O. Box 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McGuirk","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Kyoung","family":"Tiger","sequence":"additional","affiliation":[{"name":"Division of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ 08903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi R.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ 08903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6603-185X","authenticated-orcid":false,"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple Myeloma: 2024 update on Diagnosis, Risk-stratification and Management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1243997","DOI":"10.3389\/fimmu.2023.1243997","article-title":"Molecular and immunological mechanisms of clonal evolution in multiple myeloma","volume":"14","author":"Forster","year":"2023","journal-title":"Front Immunol."},{"key":"ref_3","unstructured":"(2025, October 23). Management of Relapsed\/Refractory Multiple Myeloma. Available online: https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/5.5\/article-p552.xml."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1424925","DOI":"10.3389\/fimmu.2024.1424925","article-title":"Bispecific antibody targets and therapies in multiple myeloma","volume":"15","author":"Rees","year":"2024","journal-title":"Front Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"8034","DOI":"10.1200\/JCO.2023.41.16_suppl.8034","article-title":"Durability of Responses with Biweekly Dosing of Teclistamab in Patients with Relapsed\/Refractory Multiple Myeloma Achieving a Clinical response in the majesTEC-1 Study","volume":"41","author":"Usmani","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-020-00911-4","article-title":"Measurable residual disease in multiple myeloma: Ready for clinical practice?","volume":"13","author":"Burgos","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1007\/s00277-025-06529-1","article-title":"De-escalated Teclistamab dosing in relapsed\/refractory multiple myeloma: Czech myeloma group real-world evidence analysis","volume":"104","author":"Stork","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1200\/JCO.2022.40.16_suppl.8033","article-title":"Health-Related Quality of Life in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM) Treated with Teclistamab, a B-Cell Maturation Antigen (BCMA) \u00d7 CD3 Bispecific Antibody: Patient-Reported Outcomes in MajesTEC-1","volume":"40","author":"Martin","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: Advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(24)00005-X","article-title":"Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: Patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial","volume":"11","author":"Delforge","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_12","unstructured":"Janssen Research & Development, LLC (2025, October 23). A Multi-Arm Phase 1b Study of Teclistamab with Other Anticancer Therapies in Participants with Multiple Myeloma [Internet], Available online: https:\/\/clinicaltrials.gov\/study\/NCT04722146."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: Importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2023","journal-title":"Blood Adv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3324\/haematol.2023.283590","article-title":"The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma","volume":"109","author":"Hammons","year":"2023","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-025-01254-4","article-title":"Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): Experience from 609 patients","volume":"15","author":"Chunara","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2643-3230.BCD-24-0124","article-title":"T Cell\u2013Redirecting Bispecific Antibodies in Multiple Myeloma: Optimal Dosing Schedule and Duration of Treatment","volume":"5","author":"Rasche","year":"2024","journal-title":"Blood Cancer Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: A systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-025-01282-0","article-title":"Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma","volume":"15","author":"Mohan","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_22","unstructured":"(2025, October 23). FDA Approves Teclistamab-Cqyv for Relapsed or Refractory Multiple Myeloma|FDA [Internet], Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e867","DOI":"10.1016\/S2352-3026(23)00240-5","article-title":"MRD-guided treatment cessation in multiple myeloma","volume":"10","author":"Derman","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-025-01259-z","article-title":"Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): An International Myeloma Working Group Study","volume":"15","author":"Tan","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Derman, B., Tan, C., Steinfield, I., Wilson, F.R., Lin, D., Wu, B., Fernandez, M., Fowler, J., Paner-Straseviciute, A., and Kim, N. (2025). Real-World Evidence Evaluating Teclistamab in Patients with Relapsed\/Refractory Multiple Myeloma: A Systematic Literature Review. Cancers, 17.","DOI":"10.3390\/cancers17071235"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","article-title":"Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Garfall","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood-2024-200181","article-title":"Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed\/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies","volume":"144","author":"Costa","year":"2024","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2022-159711","article-title":"Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study","volume":"140","author":"Searle","year":"2022","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N. Engl. J. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3569\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:08:45Z","timestamp":1762330125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":29,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cancers17213569"],"URL":"https:\/\/doi.org\/10.3390\/cancers17213569","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]}}}